Ann Hoffman

VP Strategic Development at Alturas Analytics

Ann Hoffman's work experience includes holding the position of VP Strategic Development at Alturas Analytics, Inc. since July 2019. In this role, they lead business planning strategies and identifies opportunities for expansion and growth. Prior to this, they served as the Director of Business Development at Alturas Analytics, Inc. and Director of Business Development & Executive Account Manager at Vitalea Science, Inc. where they specialized in using Accelerator Mass Spectrometry technology for exploring drug candidates. Ann also worked as a Sr. Business Development Executive at Torion Technologies and as a Strategic Accounts Manager at Tandem Labs. Their earlier roles include working as a Field Marketing Representative at SCIEX, a Marketing Manager at ThermoFischer Scientific, and as a Scientist at the Center for Human Toxicology University of Utah.

Ann Hoffman attended Florida Atlantic University, where they studied but did not earn a degree.

Links

Previous companies


Org chart


Teams


Offices

This person is not in any offices


Alturas Analytics

At Alturas Analytics, we deliver results on time with the highest level of integrity. Our business is built on developing long term collaborations with our clients by providing advanced MS/MS solutions through a focused emphasis on teamwork, communication and exceptional science. Alturas has a proven record with complex analysis supporting drug candidates for the pharmaceutical and biotechnology industries, from discovery through phase IV clinical trials. The company operates in a GLP environment using validated operational processes in strict adherence to internal SOPs and applicable global regulations. Bioanalytical services routinely performed include the following: • GC-MS/MS and LC-MS/MS bioanalysis – allows for the broadest range of chemical properties across a wide mass range • GLP and non-GLP bioanalysis of large and small molecules in any matrix • Quantitative Antibody Drug Conjugates (ADC) analysis • Biomarker quantitation • Protein binding estimations • Dried Blood (DBS) and Matrix Spot (DMS) analysis (limited sample volume ex. pediatrics, CSF, tears) Ensuring that a project is completed on time to a company's specifications demands clear lines of communication before, during, and after a study's completion. Clients have direct access to a team of professionals who understand the critical nature of the business. An Alturas Study Director is assigned to each client based on their working knowledge with compounds of similar chemical properties. Comments & Feedback: "Thanks. We owe a lot to Alturas for the great nonclinical and clinical bioanalytical support for the program. Happy 2013!"​ January 2013: Comment from a Sponsor after receiving FDA Approval. “You solved all of our bioanalytical problems.” Comment from a Sponsor after the Alturas Team was able to address technical difficulties. "Five Stars. Would definitely use Alturas again for upcoming projects."​ Comment from a Sponsor in 2016.


Employees

51-200

Links